Table 2 Logistic regression analysis of predictive factors for recurrence of CSDH
| Â | p value | OR (95% CI) |
|---|---|---|
Model 1 | Â | Â |
 Gender | 0.998 | NA |
 Age (years) | 0.362 | 0.949 (0.847–1.063) |
 Hypertension | 0.085 | 0.060 (0.002–1.474) |
 Diabetes | 0.514 | 0.419 (0.031–5.718) |
 Antiplatelet and/or anticoagulant use | 0.101 | 14.836 (0.590-372.953) |
 Bilateral hematoma | 0.998 | NA |
 History of trauma | 0.861 | 0.839 (0.117–6.008) |
 Mild brain atrophy | 0.320 | 1 |
 Moderate brain atrophy | 0.131 | 10.816 (0.491-238.388) |
 Severe brain atrophy | 0.999 | NA |
 Hematoma thickness | 0.313 | 2.885 (0.368–22.592) |
 Midline shift | 0.809 | 0.748 (0.071–7.850) |
 Neomembrane in CT* | 0.019 | 56.135 (1.916-1644.653) |
Model 2 | Â | Â |
 Gender | 0.998 | NA |
 Age (years) | 0.551 | 0.963 (0.851–1.090) |
Hypertension | 0.162 | 0.109 (0.005–2.441) |
 Diabetes | 0.572 | 0.488 (0.040–5.905) |
 Antiplatelet and/or anticoagulant use | 0.099 | 14.848 (0.603-347.929) |
 History of trauma | 0.891 | 0.872 (0.125–6.088) |
 Bilateral hematoma | 0.998 | NA |
 Mild brain atrophy | 0.528 | 1 |
 Moderate brain atrophy | 0.259 | 6.586 (0.250-173.249) |
 Severe brain atrophy | 0.999 | NA |
 Hematoma thickness | 0.347 | 2.715 (0.339–21.774) |
 Midline shift | 0.586 | 0.498 (0.040–6.125) |
 Hematoma cavity separation in CT* | 0.019 | 40.173 (1.833-880.678) |
Model 3 | Â | Â |
 Gender | 0.997 | NA |
 Age (years) | 0.266 | 0.914 (0.780–1.071) |
Hypertension | 0.161 | 0.114 (0.005–2.373) |
Diabetes | 0.797 | 1.409 (0.104–19.141) |
Antiplatelet and/or anticoagulant use | 0.869 | 1.285 (0.065–25.561) |
Bilateral hematoma | 0.998 | NA |
History of trauma | 0.451 | 2.376 (0.251–22.522) |
Mild brain atrophy | 0.794 | 1 |
Moderate brain atrophy | 0.498 | 3.968 (0.074-212.904) |
Severe brain atrophy | 0.999 | NA |
Hematoma thickness | 0.704 | 1.593 (0.144–17.632) |
Midline shift | 0.446 | 0.287 (0.012–7.131) |
Hematoma cavity separation or* Neomembrane during endoscopy | 0.008 | 45.822 (2.666-787.711) |